Current situation of zalutumumab

Bibliography

• Harari PM, Huang SM. Searching for reliable epidermal growth factor receptor response predictors. Clin Cancer Res 2004;10:691-700
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170-6
   PubMed Web of Science ®Google Scholar
• Dassonville O, Formento JL, Francoual M, et al. Expresion of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-78.El 63
   PubMed Web of Science ®Google Scholar
• Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41(3):453-60
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expresion in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5
   PubMed Web of Science ®Google Scholar
• Dragovich T, McCoy S, Fenoglio-preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24(30):4922-7
   PubMed Web of Science ®Google Scholar
• Lordick F, Lorenzen S, Hegewisch-becker SG, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement). J Clin Oncol 2007;25:4526
   PubMed Web of Science ®Google Scholar
• Burtness B. Her signaling in pancreatic cancer. Expert Opin Biol Ther 2007;7(6):823-9
   PubMed Web of Science ®Google Scholar
• Giltnane JM, Rydén L, Cregger M, et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007;25(21):3007-14
   PubMed Web of Science ®Google Scholar
• Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumours. Cancer Control 2007;14(3):295-304
   PubMedGoogle Scholar
• Cohen D, Lane B, Jin T, et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. Clin Genitourin Cancer 2007;5(4):264-70
   PubMed Web of Science ®Google Scholar
• Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 2005;74(1):77-86
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25(16):2288-94
   PubMed Web of Science ®Google Scholar
• Edwards J, Traynor P, Munro AF, et al. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006;12(1):123-30
   PubMed Web of Science ®Google Scholar
• Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007;106(3):513-20
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;18s:32s-40s
   Google Scholar
• Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001;18s:41s-44s
   Google Scholar
• Nyati MK, Morgan MA, Feng FV, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6:876-85
   PubMed Web of Science ®Google Scholar
• Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006;6(11):1539-52
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC. The evolving role of cetuximab in non-small cell lung cancer. Clin Cancer Res 2006;12(14 Pt 2):4432s-4435s
   PubMed Web of Science ®Google Scholar
• Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumours. Ann Pharmacother 2006;40(2):241-50
   PubMed Web of Science ®Google Scholar
• Rivera F, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008;19(2):99-113
   PubMed Web of Science ®Google Scholar
• Rivera F, Vega-Villegas ME, López- Brea MF, Mórquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncologica 2008;47(1):9-19
   PubMed Web of Science ®Google Scholar
• Ruuls SR, Lammerts van Bueren JJ, van de Winkel JGJ, Parren PWHI. Novel human antibody therapeutics: the age of the umabs. Biotechnol J 2008;3:1-15
   Google Scholar
• Lammerts van Bueren JJ, Bleeker WK, Brännström A, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008;105(16):6109-14
   PubMed Web of Science ®Google Scholar
• Dechant M, Lammerts van Bueren J, Peipp M, et al. Impact of antibody Fc carbohydrate fucosylation on antibody-dependent cellular cytotoxicity by HuMax-EGFr-A fully human epidermal growth factor receptor antibody [abstract 2543]. Proc ASCO-06
   Google Scholar
• Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004;173(7):4699-707
   PubMed Web of Science ®Google Scholar
• Lo K-M, Lan Y, Zhang X, et al. The role of ADCC effector unction in the anti-tumour efficacy of anti-EGFR antibodies in a mouse xenograft model [abstract A123]. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston); 2003
   Google Scholar
• Zhang W, Gordon M, Schultheis AM, et al FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25(24):3712-8
   PubMed Web of Science ®Google Scholar
• Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27(7):1122-9
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66(15):7630-8
   PubMed Web of Science ®Google Scholar
• Peipp M, Schneider-Merck T, Dechant M, et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 2008;180(6):4338-45
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578-87
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54
   PubMed Web of Science ®Google Scholar
• Bastholt L, Specht L, Jensen K, et al. A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a Phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (SCCHN) [abstract 5530]. Proc ASCO-05
   Google Scholar
• Van Cutsem E, Nowacki M, Lang I, et al. Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement). J Clin Oncol 2007;25:4000
   Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-9
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract 2]. J Clin Oncol 2008;26(Suppl):2
   Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34
   PubMed Web of Science ®Google Scholar
• Butts CA, Bodkin D, Middleman EL, et al. Randomized Phase II study of gemcitabine plus cisplatin, with or without Cetuximab, as first-line therapy for patients with advanced or metastatic non–small-cell lung cancer. J Clin Oncol 2007;25(36):5777-84
   PubMed Web of Science ®Google Scholar
• Rosell R, Robinet G, Szczesna A, et al. Randomized Phase II study of cetuximab plus cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008;19(2):362-9
   PubMed Web of Science ®Google Scholar
• Lynch T, Patel T, Dreisbach L, et al. A randomized multicenter Phase III study of Cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(8 Suppl 4):S340-1
   Web of Science ®Google Scholar
• Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, Phase III study of Cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). 2008 ASCO Annual Meeting, abstract 3. Updated information presented at the ASCO meeting; 2008
   Google Scholar
• Atkins D, Reiffen KA, Tgtmeier CL, et al. Inmunohistochemical detection of EGFR in paraffin-embedded tumour tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901
   PubMed Web of Science ®Google Scholar
• Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 2005;41:1383-92
   PubMed Web of Science ®Google Scholar
• Younes M. Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy? J Clin Oncol 2005;23:923. Reply: Saltz L, 923-924
   PubMedGoogle Scholar
• Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-46
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumours does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8
   PubMed Web of Science ®Google Scholar
• Defize LH, Boonstra J, Meisenhelder J, et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989;109:2495-507
   PubMed Web of Science ®Google Scholar
• Bellot F, Moolenaar W, Kris R, et al. Highaffinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses. J Cell Biol 1990;110:491-502
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26(35):5705-12
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007;25(22):3238-45
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66(8):3992-5
   PubMed Web of Science ®Google Scholar
• Romagnani E, Martin V, Ghisletta M, et al. EGFR gene status, K-Ras mutation and PTEN expression predict cetuximab response in metastatic colorectal cancer (mCRC) [absract: 427]. Proc 2007 Gastrointestinal Cancers Symposium
   Google Scholar
• Personeni N, De Schutter J, De Hertogh G, et al. Response prediction to cetuximab-based therapy: The role of EGFR copy number by fluorescence in situ hybridization and downstream effectors gene mutations [abstract: 400]. Proc 2007 Gastrointestinal Cancers Symposium
   Google Scholar
• Finocchiaro G, Cappuzzo F, Jänne PA, et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement). J Clin Oncol 2007;25:4021
   Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69(5):1851-7
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25(22):3230-7
   PubMed Web of Science ®Google Scholar